Ethics approval and consent to participate Ethical approval for this study was obtained from the University of Tasmania Human Research Ethics Committee (HREC
J Nucl Med (2017) 58:85360
[DOI] [PMC free article] [PubMed] [Google Scholar] 98.Frias J.P., Davies M.J., Rosenstock J., Perez Manghi F.C., Fernandez Lando L., Bergman B.K., Liu B., Cui X., Brown K., SURPASS-2 Investigators Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Glucagon-like peptide-1 receptor (GLP-1) agonists are an effective treatment for controlling blood glucose levels in people with type 2 diabetes, particularly those who do not respond, or stop responding to, first-line treatments, such as There are many versions of GLP-1 drugs, including: liraglutide(Victoza), which people inject daily semaglutide (Rybelsus), an oral tablet which people take once daily dulaglutide(Trulicity), which people inject once a week semaglutide (Ozempic/ Wegovy), which people inject once a week exenatide(Bydureon), which people inject once a week
